Viruses

Hilltop Holdings Inc. Announces Change in Location of the 2020 Annual Meeting of Stockholders to a Virtual-Only Format

Thursday, July 9, 2020 - 10:00pm

Hilltop Holdings Inc. (NYSE: HTH) (Hilltop) determined that, due to public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, the location of Hilltops 2020 Annual Meeting of Stockholders (the Annual Meeting) has been changed to a virtual-only format.

Key Points: 
  • Hilltop Holdings Inc. (NYSE: HTH) (Hilltop) determined that, due to public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, the location of Hilltops 2020 Annual Meeting of Stockholders (the Annual Meeting) has been changed to a virtual-only format.
  • As previously announced, the Annual Meeting will be held on Thursday, July 23, 2020, at 10:00 a.m., Dallas, Texas local time.
  • Voting now at www.proxyvote.com will ensure your representation at the Annual Meeting regardless of whether you participate in the Annual Meeting.
  • The Proxy Statement for the Annual Meeting and the Annual Report to Stockholders for the fiscal year ended December 31, 2019 are available at www.proxyvote.com .

AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus

Thursday, July 9, 2020 - 6:31pm

NEW YORK, July 9, 2020 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic.

Key Points: 
  • NEW YORK, July 9, 2020 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on its effort to identify compounds to potentially address the COVID-19 pandemic.
  • These compounds were tested for their ability to block replication of the Influenza virus in human cells, from which several active compounds were found.
  • "This is encouraging progress, demonstrating the importance of machine learning to accelerate pharmaceutical research," commented Anthony Hayes, CEO of AIkido.
  • The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Effectory: Good Crisis Communication Is Essential for Productivity During the Coronavirus Situation

Thursday, July 9, 2020 - 4:31pm

What lessons can we learn from employee experiences during the first wave of coronavirus cases?

Key Points: 
  • What lessons can we learn from employee experiences during the first wave of coronavirus cases?
  • Employees who are satisfied with the way in which their organization communicates and manages the crisis can perform better and get more work done.
  • On average, 60 percent of employees were unable to maintain a good work-life balance during the first wave of coronavirus cases.
  • This percentage was highest (62%) at the start of the coronavirus crisis and has barely reduced since.

Effectory: Good Crisis Communication Is Essential for Productivity During the Coronavirus Situation

Thursday, July 9, 2020 - 4:31pm

What lessons can we learn from employee experiences during the first wave of coronavirus cases?

Key Points: 
  • What lessons can we learn from employee experiences during the first wave of coronavirus cases?
  • Employees who are satisfied with the way in which their organization communicates and manages the crisis can perform better and get more work done.
  • On average, 60 percent of employees were unable to maintain a good work-life balance during the first wave of coronavirus cases.
  • This percentage was highest (62%) at the start of the coronavirus crisis and has barely reduced since.

R+D Custom Automation Has Announced an Agreement with SiO2 Materials Science

Thursday, July 9, 2020 - 1:38pm

LAKE VILLA, Ill., July 9, 2020 /PRNewswire/ --R+D Custom Automation, a privately-owned U.S. provider of fully customized automation systems, has announced an agreement with SiO2 Materials Science.

Key Points: 
  • LAKE VILLA, Ill., July 9, 2020 /PRNewswire/ --R+D Custom Automation, a privately-owned U.S. provider of fully customized automation systems, has announced an agreement with SiO2 Materials Science.
  • SiO2, a privately-owned U.S. advanced materials science corporation, was recently awarded a $143 million contract with the federal government as part of the Operation Warp Speed initiative.
  • The agreement accelerates the production of SiO2's patented plastic vials for storing novel coronavirus (SARS-CoV-2) vaccines and therapeutics.
  • According to Lawrence Ganti, President of Customer Operations at SiO2, the SiO2 vials are the only alternative to glass.

CENTOGENE Announces the Scientific Publication of a holistic solution in the preventive testing of COVID-19

Thursday, July 9, 2020 - 11:30am

The paper describes innovative testing solutions in the fight against COVID-19 pandemic and contributes to the global understanding of the novel Coronavirus.

Key Points: 
  • The paper describes innovative testing solutions in the fight against COVID-19 pandemic and contributes to the global understanding of the novel Coronavirus.
  • Furthermore, it discusses the Companys science-backed Coronavirus initiatives, and how these can provide a testing blueprint for the medical community.
  • The holistic solution is also the basis for our service to airport based mobility, like at the Frankfurt airport.
  • CENTOGENE Contact: Ben Legg Corporate Communications press@centogene.com Media Contact: FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com

ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model

Thursday, July 9, 2020 - 11:36am

These latest results confirmed their hypothesis by demonstrating that cell lines infected with a type of Coronavirus had decreased viral replication when supplemented with NR.

Key Points: 
  • These latest results confirmed their hypothesis by demonstrating that cell lines infected with a type of Coronavirus had decreased viral replication when supplemented with NR.
  • The collaborative research team also found that the activity of antiviral PARP enzymes was upregulated by boosting NAD pharmacologically.
  • The next steps are animal and human trials against SARS-CoV-2, reports Dr. Charles Brenner, a co-author of the study and ChromaDex Chief Scientific Advisor.
  • The team of investigators used a multi-pronged approach involving a form of Coronavirus and performed experiments in multiple separate cell models.

Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea™ COVID-19 Assay Kit and Expands Utility with Successful EUA Amendment

Thursday, July 9, 2020 - 10:00am

In mid-May, Applied DNA received Emergency Use Authorization (EUA) for a high sensitivity, high-throughput complex molecular test for SARS-CoV-2, the coronavirus that causes COVID-19.

Key Points: 
  • In mid-May, Applied DNA received Emergency Use Authorization (EUA) for a high sensitivity, high-throughput complex molecular test for SARS-CoV-2, the coronavirus that causes COVID-19.
  • The Linea COVID-19 SARS-CoV-2 Assay Kit is a real-time polymerase chain reaction (RT-PCR) test for the qualitative detection of SARS-CoV-2 RNA in respiratory specimens.
  • It provides a high-throughput solution to help laboratories address the urgent need for patient testing during the Coronavirus pandemic.
  • ADCL, the Companys new subsidiary was formed to enable clinical testing of patient specimens using methods developed by the Companys research teams.

UK Real Estate Company Hondo Enterprises in Partnership With Savills to Use BioProtectUs™ System in United Kingdom

Thursday, July 9, 2020 - 8:00am

LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.

Key Points: 
  • LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.
  • The system, which features a water-based anti-microbial called BIOPROTECT, was independently verified by a third party to eradicate SARS-CoV-2 from surfaces for more than six weeks.
  • SARS-CoV-2 is the unique coronavirus that causes COVID-19.
  • Hondo Enterprises is a property investment, development and asset management company specialising in transactions in Central London.

UK Real Estate Company Hondo Enterprises in Partnership With Savills to Use BioProtectUs™ System in United Kingdom

Thursday, July 9, 2020 - 8:00am

LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.

Key Points: 
  • LONDON, July 9, 2020 /PRNewswire/ --Hondo Enterprises, in partnership with Savills, has become the first and only company in the United Kingdom to utilise the BIOPROTECTUs system offered by BioSupplies.com, LLC in the United Kingdom.
  • The system, which features a water-based anti-microbial called BIOPROTECT, was independently verified by a third party to eradicate SARS-CoV-2 from surfaces for more than six weeks.
  • SARS-CoV-2 is the unique coronavirus that causes COVID-19.
  • Hondo Enterprises is a property investment, development and asset management company specialising in transactions in Central London.